Samaritan Pharmaceuticals, Inc. Receives Pricing Approval in Greece for Rapydan(R) and Launches Novel Product
LAS VEGAS--(BUSINESS WIRE)--Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new and innovative therapeutic drugs, announced today that it has received pricing approval for Rapydan® from the Greek Ministry of Development and is launching the novel rapid-onset anesthetic patch in Greece this week.